In HER2-positive breast cancer, the new β-TrCP-343aa isomer encoded by circular RNA (circ-β-TrCP) binds competitively to NRF2, blocking its ubiquitination and degradation, resulting in over-activation of NRF2. Here, BTRC is linked to breast carcinoma.